Clinical Trials Directory

Trials / Completed

CompletedNCT05352997

Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients

Key Factors of Target Serum Concentrations Attainment From Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients

Status
Completed
Phase
Study type
Observational
Enrollment
156 (actual)
Sponsor
Centre Hospitalier Universitaire de Nīmes · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The population of these monocentric and retrospective study includes patients hospitalized in one of the critical care services of Nîmes' community hospital. The objective is to determine the key factors that lead to satisfactory beta-lactams serum concentrations in critically ill patients. Clinical and biological features, as well as risk scores are collected and recorded into an electronic Case Report Form. The primary outcome is to show the main characteristics related to adequate beta-lactams serum concentrations in critically ill inpatients. Secondary outcomes include the key factors related to inadequate beta-lactams serum concentrations in critically ill inpatients, Therapeutic Drug Monitoring (TDM) impact in the achievement of target beta-lactams serum concentration and the correlation between Aminoglycosides and Beta-lactams serum concentrations. Do both antibiotics have similar elimination kinetics ?

Conditions

Timeline

Start date
2018-01-01
Primary completion
2022-12-31
Completion
2022-12-31
First posted
2022-04-29
Last updated
2025-12-04

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05352997. Inclusion in this directory is not an endorsement.

Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients (NCT05352997) · Clinical Trials Directory